CAJ | 학술논문

目的：评价椎基底动脉供血不足应用丁咯地尔与疏血通治疗的临床疗效。方法216例椎基底动脉供血不足患者随机分成对照组和试验组,各108例,对照组患者应用丁咯地尔进行治疗,试验组患者同时联合应用疏血通进行治疗,疗程14 d,对两组患者的治疗显效率、基底动脉和椎动脉收缩血流改善情况进行比较。结果对照组患者的治疗显效率为80.6%,试验组患者的治疗显效率为93.5%,两组比较差异具有统计学意义(P<0.05)；试验组患者治疗后基底动脉、双侧椎动脉的收缩血流改善程度优于对照组患者的收缩血流改善程度,两组比较差异具有统计学意义(P<0.05)。结论椎基底动脉供血不足应用疏血通与丁咯地尔联合治疗,二者发挥协同作用,能够有效的改善患者头颈部动脉循环、增加血流供应、显著地改善患者的临床症状、促进患者的康复,治疗效果优于丁咯地尔单独应用,具有临床推广应用价值。
목적：평개추기저동맥공혈불족응용정각지이여소혈통치료적림상료효。방법216례추기저동맥공혈불족환자수궤분성대조조화시험조,각108례,대조조환자응용정각지이진행치료,시험조환자동시연합응용소혈통진행치료,료정14 d,대량조환자적치료현효솔、기저동맥화추동맥수축혈류개선정황진행비교。결과대조조환자적치료현효솔위80.6%,시험조환자적치료현효솔위93.5%,량조비교차이구유통계학의의(P<0.05)；시험조환자치료후기저동맥、쌍측추동맥적수축혈류개선정도우우대조조환자적수축혈류개선정도,량조비교차이구유통계학의의(P<0.05)。결론추기저동맥공혈불족응용소혈통여정각지이연합치료,이자발휘협동작용,능구유효적개선환자두경부동맥순배、증가혈류공응、현저지개선환자적림상증상、촉진환자적강복,치료효과우우정각지이단독응용,구유림상추엄응용개치。
Objective To evaluate the clinical effect of buflomedil and Shuxuetong in the treatment of vertebrobasilar ischemia. Methods A total of 216 vertebrobasilar ischemia patients were randomly divided into control group and experimental group, with 108 cases in each group. The control group received buflomedil for treatment, while the experimental group received additional Shuxuetong, and the treatment period lasted for 14 d. The comparisons were made on the changes of effective rate and improvement of systolic blood flow in basilar artery and vertebral artery in the two groups. Results The effective rate of the control group was 80.6%, and that of the experimental group was 93.5%. The difference between the two groups had statistical significance (P<0.05). After treatment, the improvements of systolic blood flow in basilar artery and vertebral artery were much better in the experimental group than in the control group, and there was significant difference between the two groups (P<0.05). Conclusion The combination treatment by buflomedil and Shuxuetong for vertebrobasilar ischemia can effectively improve head and neck arterial circulation, blood supply, and the clinical symptoms and rehabilitation of patients. Its curative effect is better than the single treatment by buflomedil, and the therapy is worth clinical promotion and application.